Glaxo Group Limited

Smithkline Beecham Corporation

Other

David George Allen

Suzanne Elaine Keeling

Alison Judith Redgrave

Michael David Barker

Brian Cox

Richard Peter Charles Cousins

Heather Hobbs

Joanna Victoria Geden

Diane Mary Coe

Anthony William James Cooper

Chuen Chan

Caroline Mary Cook

Christopher David Edlin

Thomas Davis Roper, Iv

Julie Nicole Hamblin

Hazel Joan Dyke

David E Bays

Michael D Dowle

Paul Spencer Jones

Charlotte Jane Mitchell

Mika Lindvall

Colin David Eldred

William L Mitchell

Stephen Swanson

Stefan Senger

Shiping Xie

Naimisha Trivedi

Frank Ellis

Martin Redpath Johnson

David House

Caroline Whitworth

Paul Martin Gore

Sadie Vile

Steven Leslie Sollis

Caroline Jane Day

Leanda Jane Kindon

Reshma Manesh Chudasama

Caroline Wilson

Rodger Phillip Barnett

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

N-pyrazolyl carboxamides as CRAC channel inhibitors

The invention provides N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl) (methyl)amino]octanoyl}amino)benzamide, whose formula is or a salt thereof, such as the monohydrochloride salt thereof. The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis (e.g. allergic and/or non-allergic rhinitis).

Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

The invention provides novel compounds which are agonists of the adenosine 2A receptor along with pharmaceutical compositions thereof, and methods of administering such compounds.

Purine derivatives as agonists of the adenosine A2A receptor

The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or &#x2014;(CH)OH; Ris a hydrogen atom (H), methyl or Cfluoroalkyl; Ris a hydrogen atom (H) or Calkyl; Ris optionally substituted branched Calkyl, optionally substituted Ccycloalkyl, optionally substituted mono-unsaturated-Ccycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which nand nindependently are 1 or 2; and Y is O, S, SO, or NR; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.

2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives

2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2 receptor are described.

2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives

There are provided according to the invention novel compounds of formula (I) wherein R , R , and R are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Piperidineacetic acid derivatives useful as fibrinogen antagonist agent

Growing community of inventors

Stevenage, United Kingdom

David George Allen